课题基金 / 基金详情

SYNTHESIS OF ADRIAMYCIN SUGARS AND THIENAMYCIN

SYNTHESIS OF ADRIAMYCIN SUGARS AND THIENAMYCIN
阿霉素糖和硫霉素的合成
批准号:
3171839
负责人:
M MARK MIDLAND
金额:
$2.88万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-02-01 至 1986-01-31

项目摘要

项目成果

M MARK MIDLAND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Adriamycin, a member of the anthracycline family of antibiotics, has been found to be highly effective against a wide variety of cancers. Thienamycin is a Beta-lactam antibiotic isolated from streptomyces cattleya that has shown unusually high potency against both gram-positive and gram-negative bacteria. The chirality in these molecules plays a crucial role in their biological activities. Hence the synthesis of the optically active forms of these compounds is important. We have recently developed two new methods for preparing optically-active molecules: asymmetric reductions via trialkylboranes, and control of stereochemistry at the migration terminus of organoborate rearrangements. The asymmetric reduction of propargyl ketones makes essentially optically-pure propargyl alcohols readily available, and the acetylene handle makes alcohols attractive intermediates for further elaboration. The study of organoborane rearrangements has made optically-active allylboranes readily accessible for the first time. Addition of these organoboranes to a ketone or aldehyde produces optically-active alcohols with several contiguous chiral centers. These processes will be used in a novel lactone ring expansion reaction that provides a series of closely related chiral lactones that can be applied to both thienamycin and the sugar portion of adriamycin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
ASYMMETRIC REDUCTIONS VIA TRIALKYLBORANES
海外基金